---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-009351"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:45:55.782693+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyadic FY2024: revenue $3.5M (+21%), net loss $5.8M ($0.20/shr), cash $9.3M

## Summary
- Revenue $3.495M, up from $2.899M in 2023; driven by $1M Proliant license and $890k Inzymes success fees.
- Net loss $5.809M ($0.20 per share), improved from $6.795M ($0.24 per share) in 2023.
- Cash and investment-grade securities $9.288M at Dec 31, 2024 vs $7.273M at year-end 2023.
- Up to $7.5M in grants from CEPI (up to $2.4M for Dyadic) and Gates Foundation for C1 platform.
- Human Serum Albumin commercial launch expected Q2 2025; DNase1 advancing with EU CDMO partnership.

## SEC filing metadata
- accession: 0001437749-25-009351
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774925009351/0001437749-25-009351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774925009351/dyai20240925_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-009351
- JSON: https://secwatch.observer/filing/0001437749-25-009351.json
- Plain text: https://secwatch.observer/filing/0001437749-25-009351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.